Astral Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 16, 2025, 3:26 pm

Competitors of Astral Ltd

All Competitor Stocks of Astral Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:25 pm

Below is a detailed analysis of the quarterly data for Astral Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,361.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,681.00 Cr. (Mar 2025) to 1,361.00 Cr., marking a decrease of 320.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,176.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,380.00 Cr. (Mar 2025) to 1,176.00 Cr., marking a decrease of 204.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 302.00 Cr. (Mar 2025) to 185.00 Cr., marking a decrease of 117.00 Cr..
• For OPM %, as of Jun 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 14.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
• For Interest, as of Jun 2025, the value is 12.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 72.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 65.00 Cr. (Mar 2025) to 72.00 Cr., marking an increase of 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 110.00 Cr.. The value appears to be declining and may need further review. It has decreased from 236.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 126.00 Cr..
• For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Mar 2025) to 28.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 79.00 Cr.. The value appears to be declining and may need further review. It has decreased from 178.00 Cr. (Mar 2025) to 79.00 Cr., marking a decrease of 99.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.02. The value appears to be declining and may need further review. It has decreased from 6.67 (Mar 2025) to 3.02, marking a decrease of 3.65.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:25 pm

Growth

Last Updated: September 4, 2025, 11:55 pm

Balance Sheet

Last Updated: August 11, 2025, 1:40 pm

Below is a detailed analysis of the balance sheet data for Astral Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 27.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 27.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,590.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,161.00 Cr. (Mar 2024) to 3,590.00 Cr., marking an increase of 429.00 Cr..
• For Borrowings, as of Mar 2025, the value is 233.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 119.00 Cr. (Mar 2024) to 233.00 Cr., marking an increase of 114.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,198.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,188.00 Cr. (Mar 2024) to 1,198.00 Cr., marking an increase of 10.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 5,048.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,496.00 Cr. (Mar 2024) to 5,048.00 Cr., marking an increase of 552.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,712.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,299.00 Cr. (Mar 2024) to 2,712.00 Cr., marking an increase of 413.00 Cr..
• For CWIP, as of Mar 2025, the value is 116.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2024) to 116.00 Cr., marking a decrease of 35.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,220.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,046.00 Cr. (Mar 2024) to 2,220.00 Cr., marking an increase of 174.00 Cr..
• For Total Assets, as of Mar 2025, the value is 5,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,496.00 Cr. (Mar 2024) to 5,048.00 Cr., marking an increase of 552.00 Cr..

Notably, the Reserves (3,590.00 Cr.) exceed the Borrowings (233.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Astral Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 19.50. This value is within the healthy range. It has decreased from 20.33 (Mar 24) to 19.50, marking a decrease of 0.83.
• For Diluted EPS (Rs.), as of Mar 25, the value is 19.50. This value is within the healthy range. It has decreased from 20.33 (Mar 24) to 19.50, marking a decrease of 0.83.
• For Cash EPS (Rs.), as of Mar 25, the value is 28.34. This value is within the healthy range. It has increased from 27.63 (Mar 24) to 28.34, marking an increase of 0.71.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 134.42. It has increased from 121.46 (Mar 24) to 134.42, marking an increase of 12.96.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 134.46. It has increased from 121.51 (Mar 24) to 134.46, marking an increase of 12.95.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 216.82. It has increased from 209.72 (Mar 24) to 216.82, marking an increase of 7.10.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 36.70. This value is within the healthy range. It has increased from 35.70 (Mar 24) to 36.70, marking an increase of 1.00.
• For PBIT / Share (Rs.), as of Mar 25, the value is 27.65. This value is within the healthy range. It has decreased from 28.36 (Mar 24) to 27.65, marking a decrease of 0.71.
• For PBT / Share (Rs.), as of Mar 25, the value is 26.12. This value is within the healthy range. It has decreased from 27.27 (Mar 24) to 26.12, marking a decrease of 1.15.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 19.29. This value is within the healthy range. It has decreased from 20.29 (Mar 24) to 19.29, marking a decrease of 1.00.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.47. This value is within the healthy range. It has decreased from 20.30 (Mar 24) to 19.47, marking a decrease of 0.83.
• For PBDIT Margin (%), as of Mar 25, the value is 16.92. This value is within the healthy range. It has decreased from 17.02 (Mar 24) to 16.92, marking a decrease of 0.10.
• For PBIT Margin (%), as of Mar 25, the value is 12.75. This value is within the healthy range. It has decreased from 13.52 (Mar 24) to 12.75, marking a decrease of 0.77.
• For PBT Margin (%), as of Mar 25, the value is 12.04. This value is within the healthy range. It has decreased from 13.00 (Mar 24) to 12.04, marking a decrease of 0.96.
• For Net Profit Margin (%), as of Mar 25, the value is 8.89. This value is within the healthy range. It has decreased from 9.67 (Mar 24) to 8.89, marking a decrease of 0.78.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.98. This value is within the healthy range. It has decreased from 9.68 (Mar 24) to 8.98, marking a decrease of 0.70.
• For Return on Networth / Equity (%), as of Mar 25, the value is 14.48. This value is below the healthy minimum of 15. It has decreased from 17.13 (Mar 24) to 14.48, marking a decrease of 2.65.
• For Return on Capital Employeed (%), as of Mar 25, the value is 19.00. This value is within the healthy range. It has decreased from 22.59 (Mar 24) to 19.00, marking a decrease of 3.59.
• For Return On Assets (%), as of Mar 25, the value is 10.35. This value is within the healthy range. It has decreased from 12.14 (Mar 24) to 10.35, marking a decrease of 1.79.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.22. It has decreased from 1.27 (Mar 24) to 1.22, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has increased from 1.77 (Mar 24) to 1.88, marking an increase of 0.11.
• For Quick Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 1. It has increased from 0.95 (Mar 24) to 0.99, marking an increase of 0.04.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.06. This value is within the healthy range. It has increased from 3.89 (Mar 24) to 6.06, marking an increase of 2.17.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 19.22. This value is below the healthy minimum of 20. It has increased from 18.43 (Mar 24) to 19.22, marking an increase of 0.79.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.12. This value is below the healthy minimum of 20. It has decreased from 13.54 (Mar 24) to 13.12, marking a decrease of 0.42.
• For Earning Retention Ratio (%), as of Mar 25, the value is 80.78. This value exceeds the healthy maximum of 70. It has decreased from 81.57 (Mar 24) to 80.78, marking a decrease of 0.79.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.88. This value exceeds the healthy maximum of 70. It has increased from 86.46 (Mar 24) to 86.88, marking an increase of 0.42.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 23.90. This value is within the healthy range. It has decreased from 33.00 (Mar 24) to 23.90, marking a decrease of 9.10.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 13.56. This value is within the healthy range. It has decreased from 19.75 (Mar 24) to 13.56, marking a decrease of 6.19.
• For Enterprise Value (Cr.), as of Mar 25, the value is 34,390.31. It has decreased from 53,110.31 (Mar 24) to 34,390.31, marking a decrease of 18,720.00.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.90. This value exceeds the healthy maximum of 3. It has decreased from 9.41 (Mar 24) to 5.90, marking a decrease of 3.51.
• For EV / EBITDA (X), as of Mar 25, the value is 34.84. This value exceeds the healthy maximum of 15. It has decreased from 55.30 (Mar 24) to 34.84, marking a decrease of 20.46.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has decreased from 9.49 (Mar 24) to 5.96, marking a decrease of 3.53.
• For Retention Ratios (%), as of Mar 25, the value is 80.77. This value exceeds the healthy maximum of 70. It has decreased from 81.56 (Mar 24) to 80.77, marking a decrease of 0.79.
• For Price / BV (X), as of Mar 25, the value is 9.62. This value exceeds the healthy maximum of 3. It has decreased from 16.80 (Mar 24) to 9.62, marking a decrease of 7.18.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has decreased from 9.49 (Mar 24) to 5.96, marking a decrease of 3.53.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness